Item 9 Labs Corp

Company Profile

Item 9 Labs Corp had its IPO on under the ticker symbol INLB.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Item 9 Labs Corp has a staff strength of 97 employees.

Stock update

Shares of Item 9 Labs Corp opened at $0.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.02 - $0.02, and closed at $0.02.

This is a -20% slip from the previous day's closing price.

A total volume of 602,688 shares were traded at the close of the day’s session.

In the last one week, shares of Item 9 Labs Corp have slipped by -20%.

Item 9 Labs Corp's Key Ratios

Item 9 Labs Corp has a market cap of $1.64 million, indicating a price to book ratio of 0.2833 and a price to sales ratio of 0.9485.

In the last 12-months Item 9 Labs Corp’s revenue was $19.69 million with a gross profit of $7.31 million and an EBITDA of $-8459747. The EBITDA ratio measures Item 9 Labs Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Item 9 Labs Corp’s operating margin was -51.01% while its return on assets stood at -5.4% with a return of equity of -47.36%.

In Q2, Item 9 Labs Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1.8%.

Item 9 Labs Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Item 9 Labs Corp’s profitability.

Item 9 Labs Corp stock is trading at a EV to sales ratio of 2.1827 and a EV to EBITDA ratio of -4.3233. Its price to sales ratio in the trailing 12-months stood at 0.9485.

Item 9 Labs Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$112.02 million

Total Liabilities

$58.81 million

Operating Cash Flow

$0

Capital Expenditure

$62845

Dividend Payout Ratio

0%

Item 9 Labs Corp ended 2024 with $112.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $112.02 million while shareholder equity stood at $52.65 million.

Item 9 Labs Corp ended 2024 with $0 in deferred long-term liabilities, $58.81 million in other current liabilities, in common stock, $-77602297.00 in retained earnings and $58.06 million in goodwill. Its cash balance stood at $183429.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Item 9 Labs Corp’s total current assets stands at $3.35 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $968016.00 compared to accounts payable of $6.85 million and inventory worth $1.90 million.

In 2024, Item 9 Labs Corp's operating cash flow was $0 while its capital expenditure stood at $62845.

Comparatively, Item 9 Labs Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.02

52-Week High

$0.53

52-Week Low

$0.01

Analyst Target Price

$

Item 9 Labs Corp stock is currently trading at $0.02 per share. It touched a 52-week high of $0.53 and a 52-week low of $0.53. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.03 and 200-day moving average was $0.11 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 2527% of the company’s stock are held by insiders while 0% are held by institutions.